Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM

Abstract

The primary goal of the present study was to examine the effects of improved glycaemic control associated with glipizide treatment on postprandial lipaemia in non-insulin-dependent diabetic patients. The metabolism of triglyceride-rich lipoproteins of intestinal origin was assessed by measuring the retinyl palmitate content in plasma and the Svedberg flotation index (Sf) > 400 and Sf 20-400 lipoprotein fractions. Fasting plasma glucose concentrations (14.5 +/- 0.5 vs 9.0 +/- 0.5 mmol/l), glycated haemoglobin levels (13.1 +/- 0.6 vs. 9.7 +/- 0.6%), and daylong plasma glucose concentrations were all significantly lower after glipizide treatment (p < 0.001). The improvement in glycaemic control was associated with increases in insulin-mediated glucose uptake (p < 0.001) and plasma post-heparin lipoprotein and hepatic lipolytic activities (p < 0.02). Both fasting plasma triglyceride (3.09 +/- 0.51 vs 2.37 +/- 0.34 mmol/l), and postprandial triglyceride concentrations (p < 0.05-0.001) were lower following glipizide treatment, associated with a significant fall in retinyl palmitate content in all three lipoprotein fractions (p < 0.02-0.001), with the most substantial decrease seen in the Sf20-400 fraction. These data indicate that glipizide-induced improvement in glycaemic control was associated with changes in the metabolism of triglyceride-rich lipoproteins of intestinal origin that would be anticipated to reduce risk of coronary heart disease in non-insulin-dependent diabetic patients.

Effects of metformin+sitagliptin versus metformin + glibenclamide combinations on lipid profile, body mass index and kidney function in Iraqi patients with type 2 diabetes mellitus.

“…In the randomized cohort study, all metforminbased groups and the placebo group experienced small but significant reduction in body weight, while there was no change in sitagliptin group [30] , these results are consistent with previous finding for both treatments [31] .…”

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus

“…In fact, various oral antidiabetic agents have been shown to improve postprandial hyperlipidemia, although this is not a universal finding. Both metformin [25, 26] and glipizide [27] can improve postprandial lipid levels in patients with poorly controlled type 2 diabetes, presumably by improving glycemic control and reducing insulin resistance. Therefore, the beneficial impact of sitagliptin on postprandial lipid levels could also be secondary to the reduction of glucose and improved metabolic balance.…”

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes

“…In fact, many different oral hypoglycaemic agents have been shown to improve postprandial lipaemia, although this is not a universal finding. Both metformin [46,47] and glipizide [48] can improve postprandial lipid levels in poorly controlled type 2 diabetic patients, presumably by improving glycaemic control and reducing insulin resistance. However, the secretagogues nateglinide and glibenclamide had no significant impact on postprandial lipaemia, despite their associated insulinotropic effect and improvement in glycaemic control [49].…”